HWBIO Presents Professional Dry Eye Management Solutions at the 56th Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists

From November 14th to 17th, 2025, the 56th Annual Scientific Congress of The Royal Australian and New Zealand College of Ophthalmologists (RANZCO 2025) was successfully held at the Melbourne Convention and Exhibition Centre. As an innovative enterprise deeply committed to the ophthalmology field, HWBIO was invited to participate in this international ophthalmology event. Showcasing its core products, the Thermal Pulsation Dry Eye Treatment Device and the Ophthalmic Ultrasonic Atomization Fumigation Therapy Device, HWBIO presented a systematic, professional, and reliable full-scenario solution for dry eye issues to global ophthalmology experts.

HWBIO® MeiboRevive Vectorted Thermal Pulsation System：Advanceddvanced Thermal Pulsation Technology

HWBl0® MeiboRevive™ Vectored Thermal Pulsation System consists of a main console,and a disposable, sterile interocular treatment instrument-the 'OcuReviver'. It uses localized electronic heating and compression on the eyelid area to treat dry eye caused by meibomian gland dysfunction.

Experts at the congress highlighted that the thermal pulsation technology utilized in the HWBIO® MeiboRevive Vectored Thermal Pulsation System is 'currently recognized globally in clinical practice as the most advanced, safest, most effective, and most comfortable physical treatment protocol.'

Professional Exchange and Abundant On-site Interaction Outcomes

During the conference, HWBIO's booth was exceptionally lively, attracting ophthalmology experts from Australia, New Zealand, Singapore, and other countries who frequently stopped to focus on the two core products. The application value of these products in different clinical scenarios (such as daily care for mild to moderate dry eye, and combination therapy for severe MGD) and their performance regarding precise technical parameters sparked constructive discussions among the expert audience. HWBIO's professional team engaged in in-depth dialogues with several internationally renowned ophthalmologists on topics including standardized clinical pathways for dry eye management and multi-dimensional efficacy evaluation systems, gathering a wealth of valuable suggestions for the global adaptation of its products.

Deepening Global Perspective, Continuously Contributing to Eye Health

This appearance at RANZCO 2025 signified that HWBIO has deepened its dialogue with the international ophthalmology community to a new level. During the exhibition, the company's dry eye diagnosis and treatment solutions received positive feedback and recognition from experts of multiple countries. 'We value every opportunity for professional exchange with our international counterparts,' stated an HWBIO representative on-site. 'The valuable insights from the global clinical frontlines will directly drive our continuous optimization of the product experience and refinement of treatment solutions, thereby providing more targeted solutions for dry eye patients in different regions and clinical environments.'

HWBIO will continue to gather clinical wisdom from around the globe, systematically integrating it into the development of new-generation products and the upgrading of existing ones. The company is committed to building a dry eye diagnosis and treatment system that more closely aligns with actual clinical needs, providing professional support for enhancing the level of global eye health services.